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Oral anticoagulation in Atrial Fibrillation 
Non-valvular atrial fibrillation (AF) represents the most common arrhythmia in clinical 
practice, currently affecting more than 8 million people independently in Europe. (1) AF 
confers a substantially increased risk for thromboembolic events and is responsible for more 
than 26% of all diagnosed ischemic strokes that are often lethal or severely disabling. In the 
western world, AF is currently diagnosed in more than 3% of the adult population without 
extrapolating the estimated undiagnosed/silent AF cases. (2) As a major future healthcare 
burden, AF prevalence increases dramatically after the age of 60 years and the ageing society 
fuels further the epidemic of AF in the next decades according to demographic forecasts. (3-4) 
While the therapeutic approach of AF consists of a multifaceted interaction of rate control, 
rhythm control and antithrombotic therapy, it is well recognized that the most beneficial 
independent management decision in those individuals concerns the issue of stroke prevention. 
(5) 
Since oral anticoagulation (OAC) effectively prevents the majority of ischemic strokes in AF, 
simple schemes for stratification of patients’ individual risk for stroke were already developed 
in the 1990s based on small cohort studies resulting in the CHADS2 score as a valid tool for 
prediction of thromboembolic events. (6) However, the CHADS2 score was not sensitive at its 
lower scoring range for thromboembolic risk. In the 2010 update of the guidelines on the 
management of AF of the European Society of Cardiology (ESC), the CHADS2 score was 
replaced by the CHA2DS2-VASc score, which is, until now, recommended to assess the risk of 
stroke in AF. (5, 7) The more sensitive CHA2DS2-VASc score covers the variables congestive 
heart failure, hypertension, age of 75 years or older, diabetes mellitus type II, previous 
stroke/transient ischemic attack or thromboembolism, vascular disease, age 65-74 years and 
female gender. However, other potential risk factors such as impaired kidney function, cancer, 
rheumatoid arthritis, obesity or smoking were not included in the model.   
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Guidelines advise initiation of OAC therapy (preferably non-Vitamin K antagonist oral 
anticoagulants [NOAC] or Vitamin K antagonists [VKA]) in AF patients with a CHA2DS2-
VASc score ≥ 2 for lowering the individual stroke risk, while an OAC approach in individuals 
with a CHA2DS2-VASc score of 0 is not recommended. (5) 
These recommendations pose a gray area for about 15% of patients with a CHA2DS2-VASc 
score of 1 who may benefit from OAC (8). Although the ESC Guidelines on the management 
of AF state that OAC in individuals with a CHA2DS2-VASc score of 1 might prevent 
thromboembolic events, serious bleeding complications, as the major downside of OAC, may 
outweigh these benefits. 
Therefore, physicians need to carefully balance the individual benefit of reducing 
thromboembolic risk with OAC against the potential harm due to an increase in bleeding risk 
in this intermediate-risk patient population. Consequently, stroke prevention in patients with a 
CHA2DS2-VASc of 1 (CHA2DS2-VASc of 2 in women) is a major challenge in clinical practice. 
Of note, a substantial number of patients is not receiving any OAC before and, even despite 
increased risk, after a first thromboembolic event. (9) Since we do not have profound data of 
randomized controlled trials, we need to rely on mainly observational data or even expert 
opinions to decide whether or not to initiate OAC in AF patients with a CHA2DS2-VASc of 1.  
 
The Net-Benefit of Oral Anticoagulation – Stroke Prevention vs. Bleeding Risk 
The risk of stroke is not homogeneous in patients with AF and strongly varies depending on 
age, comorbidities and also among populations. (8-10) However, only AF registries that 
encompass an adequately powered sample size of intermediate-risk patients enable the 
extension of knowledge regarding risk factors, outcome associations and – most importantly - 
risk evaluation of different treatment strategies. 
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There is common consensus that a thromboembolic event rate of 1% per year is needed to 
justify initiation of OAC in AF. (5, 10-11) As mentioned before, the risk of thromboembolic 
events in AF is estimated with the CHA2DS2-VASc score. The adjusted event rates per year 
within the respective score classes are displayed in Table 1. Compared to the CHADS2 score 
the CHA2DS2-VASc score became more sensitive in the lower scoring range. While individuals 
with a score of 0 have an estimated and adjusted annual stroke risk of approximately 0%, the 
event rate in AF patients presenting with a CHA2DS2-VASc score of 1 is 1.3%. (8-9) 
Considering a thromboembolic risk of >1% per year in those patients, the initiation of OAC for 
stroke prevention seems justified. However, data on the adjusted annual stroke risk are very 
variable and depend on the respective validation cohort. In this regard, data of the Euro-Heart 
Survey demonstrated an adjusted annual stroke risk of 0.6% in individuals with a CHA2DS2-
VASc score of 1. (8) As expressed by the 2016 ESC guidelines on the management of AF the 
three Population, Intervention, Comparison, Outcome and Time (PICOT) questions on relevant 
topics for the guidelines highlighted the need to investigate ischemic stroke rates in AF patients 
with a CHA2DS2-VASc score of 1 with and without OAC therapy.  Thereby, annual stroke rates 
were not equal across investigated study populations, showing an overall event rate of 1.4% 
(0.5-2.9) per 100 patient years in intermediate-risk AF individuals receiving no OAC, compared 
to 0.7% (0.1-1.3) per 100 patient years under OAC. (5, 8-10) 
Recent data from a large Swedish registry challenged the current concept of OAC in 
intermediate-risk AF patients. (12) In 12.298 enrolled participants with a CHA2DS2-VASc 
score of 1, an adjusted event rate of 0.5% to 0.9% was observed although the composite 
endpoint included transient ischemic attack (TIA), pulmonary embolism (PE), systemic 
embolism, unspecified stroke and ischemic stroke. 
Considering these data, the concept that individuals with a CHA2DS2-VASc score of 1 have an 
adequately high annual risk to merit OAC for stroke prevention needs to be questioned.  
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Providing an evidence-based approach for filling this gap of knowledge, the patients’ individual 
net clinical benefit seems to be a reasonable decision-making tool for OAC treatment. To assess 
the net-benefit of OAC in patients with AF and a CHA2DS2-VASc score of 1, the risk of 
thromboembolic events needs to be weighed against the bleeding risk – in particular intracranial 
bleeding. To estimate annual bleeding risk, the ESC guidelines on the management of AF 
recommend the use of scoring tools such as the ABC, ATRIA, ORBIT or HAS-BLED scores. 
(13-15) Since the HAS-BLED score has been validated for both NOAC and VKA use and 
mirrors an easily assessable scoring tool to elucidate the individual risk of bleeding, that might 
be used in this regard. (11, 13, 16) A detailed summary of the HAS-BLED score categories and 
their respective bleeding risks are shown in Table 1. 
Especially with VKA, the risk of major bleeding is dependent on the quality of anticoagulation 
and the patients’ adherence and compliance. In individuals reaching a therapeutic target range 
of an international normalized ratio (INR) between 2.0-3.0 with a recommended continuity of 
at least 70% of the time, the risk of major bleeding was estimated to be 1.3% per year. (11, 16) 
The respective bleeding risk associated with the HAS-BLED score classes within the lower 
range (score ≤1) is between 0.59% and 1.51%. (16-17) In the large landmark phase III trials on 
NOAC – RE-LY, ARISTOTLE, ENGAGE AF and ROCKET-AF – the risk of bleeding was 
properly assessed. (18-21) Compared to warfarin, the risk of major bleeding was significantly 
reduced with dabigatran (only 110mg bid), apixaban and edoxaban, while rates of major 
bleeding were similar to those observed with VKA in patients receiving high-dose dabigatran 
(150mg bid) and rivaroxaban. However, intracranial hemorrhage (ICH) still represents the 
major concern in individuals receiving OAC. While the sequelae of ICH seem to be less severe 
in patients receiving a NOAC, NOAC also showed a strong reduction in annual ICH rates 
compared to warfarin with an overall hazard ratio of 0.48 in the above-mentioned major 
landmark trials. (22) Interestingly, data from the Swedish hospital discharge register 
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highlighted that the risk of ischemic stroke without VKA is higher than the risk of intracranial 
bleeding almost irrespective of HAS-BLED und CHA2DS2-VASc score categories. While their 
analysis on the net clinical benefit of VKA indicated a potential benefit in patients with a 
CHA2DS2-VASc score of 1 and a HAS-BLED score of 2, an equality in risk was observed with 
a HAS-BLED score of 3. However, based on both the low number of endpoints in especially 
low and intermediate risk individuals and the observed confidence intervals, conclusions on the 
net clinical benefit that can be drawn from this investigation are limited for AF patients with a 
CHA2DS2-VASc score of 1. (23) 
Based on the annual thromboembolic risk of 0.6% to 1.3% and the individual bleeding risk of 
0.59% to 1.51%, we are currently not able to draw a conclusion concerning the net benefit of 
OAC in patients with both a CHA2DS2-VASc and HAS-BLED score of 1. Considering annual 
bleeding rates of 1.88% to 3.20% per year in patients presenting with a HAS-BLED score of 2, 
the annual risk of bleeding outweighs the thromboembolic risk associated with a CHA2DS2-
VASc score of 1, which amounts to only 0.6% to 1.3% per year. (Table 1) Therefore, OAC 
should not be considered in intermediate thromboembolic risk patients with a HAS-BLED score 
≥2. To elucidate a potential treatment benefit of OAC in CHA2DS2-VASc score of 1, a 
refinement of risk estimation in individual thromboembolic and bleeding risk is needed. 
 
Refinement of Individual Thromboembolic Risk 
Do all Thromboembolic Risk Factors Count Equally? 
Considering the clinical application of the CHA2DS2-VASc score, it covers the following easily 
available patient characteristics for the assessment of the adjusted thromboembolic risk in 
patients with AF: (5) 
 congestive heart failure (1 point) 
 hypertension (1 point) 
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 age >75 years (2 points) 
 type II diabetes mellitus (1 point) 
 stroke/TIA (2 points) 
 vascular disease (1 point) 
 age 65-74 years (1 point) 
 female gender (1 point) 
Weighing of individual risk factors: The score itself gives one scoring point for each present 
risk factor – except previous stroke/TIA and age above 75 years (with 2 points each). This 
weighing was chosen basically for practical reasons in order to make the scoring tool clinically 
useful and simple to apply at bedside. (5) However, data from China challenged this practical 
“1-point”-concept of risk estimation in the subgroup of patients with a CHA2DS2-VASc score 
of 1 by showing a different individual increase of thromboembolic risk depending on the 
particular risk factor. (24) This effect remained evident after stratification in male and female 
individuals. The most prominent risk increase was observed for “age 65-74years” followed by 
“type II diabetes mellitus”. However, AF patients presenting with diabetes mellitus type 1 aged 
below 65 years were found to be at lower risk for thromboembolic events compared to their 
type II diabetes mellitus counterparts. (25) The effect of a well-controlled type II on the 
individual thromboembolic risk remains unknown and needs to be addressed in future 
investigations. 
The lowest risk for stroke was evident in “hypertension” for female and “vascular disease” for 
male patients. Of note, the average annual risk of ischemic stroke in this analysis was 2.75% 
per year and therefore higher as reported in previous analyses on this topic.  
 
Exceptional position of female gender: Female gender has previously been suggested as a 
potential risk factor for thromboembolic events in patients with AF and has therefore been 
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included in the CHA2DS2-VASc score and the respective guidelines. (26-27) However, using 
the CHA2DS2-VASc score, it needs to be considered that female gender is not an isolated risk 
factor per se – it only counts for risk estimation in presence of an additional risk factor. Data of 
a large national Danish registry illustrated risk discrimination of male and female AF patients. 
(28) The registry yielded an annual risk for thromboembolic events that was comparable 
between male and female individuals below 75 years of age; only in patients equal or above 75 
years female gender was associated with an increased risk of thromboembolism compared to 
their male counterparts. These results suggest that female gender should not be implemented in 
risk estimation without careful prior consideration of the patients’ age. Importantly, the 
patients’ age (>65 years) conveys a strong and continuously increasing risk for thromboembolic 
events in female and male patients that also potentiates other risk factors used in the CHA2DS2-
VASc score. (29-30) 
 
Definition of Risk Factors 
In addition to the aforementioned concerns regarding the variables included in the CHA2DS2-
VASc score, the definitions of the risk factors – which may influence the estimation of the 
individual thromboembolic risk – might need to be reconsidered. This is of particular 
importance for the definitions of “congestive heart failure” and “hypertension”. 
Congestive heart failure: In large registries on AF, the presence of congestive heart failure is 
only defined as the presence of heart failure-associated symptoms (predominantly defined by 
the New York Heart Association [NYHA] classification), which may also include patients with 
heart failure with preserved ejection fraction (HFpEF). Moreover, the current definition does 
not reflect whether left ventricular ejection fraction (LVEF) is severely reduced or might be 
influenced by a recent decompensation. Similarly, information about the prognostic impact of 
a transient reduction of LVEF – possibly tachycardia-induced – with a subsequent recovery of 
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symptoms remains scarce. In this regard recent data demonstrated that patients with stable heart 
failure (detected by low N-terminal pro-B-type natriuretic peptide values) did not appear to be 
at risk of thromboembolic events. (31) Similar results were evident for individuals presenting 
with a well-controlled hypertension. (32) 
Hypertension: There is no evidence in literature concerning the definition of hypertension as a 
cardiovascular risk factor. Usually the presence of hypertension is defined as the history of 
hypertension (including anti-hypertensive treatment at the time of assessment). Since it seems 
intuitive that it has a strong impact on the discriminatory power of the CHA2DS2-VASc score, 
it might be of utmost importance to investigate whether well-controlled hypertension has the 
same predictive value for thromboembolic events in AF as not adequately controlled 
hypertension.  
A clear definition of both congestive heart failure and hypertension within the CHA2DS2-VASc 
score seems crucial for a proper assessment of the actual thromboembolic risk – especially in 
intermediate-risk individuals. While there is a major need for future investigations in this field, 
it has currently no consequence in terms of the initiation of OAK. 
 
Consideration of Additional Risk Factors 
Facing the scenario of a CHA2DS2-VASc score of 1, the use of additional risk factors which 
may help to stratify patients with potential OAC-benefit needs to be considered. These variables 
might include data on lifestyle (e.g. tobacco and ethanol abuse) or the patients’ physical 
appearance (e.g. obese vs. athletic; dementia). Of note while obesity is a well-established risk 
factor for thromboembolic events, recent data from Japan reported a low-body weight as a risk 
factor for stroke in AF patients within the general Japanese population. (33) However, those 
data might ground on a potential underuse/-dosage of (N)OAC agents, based on a frail 
appearance of the respective patients as recently described. (34) Additionally, compliance and 
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adherence of drug intake in patients with dementia might not be reasonable based on a potential 
under-use or accidental over-dosage. (35) In terms of OAC, it introduces a substantial risk of 
major bleeding without any consistent risk reduction on thromboembolic events. Therefore, the 
initiation of an antithrombotic therapy in AF patients with dementia needs to be evaluated with 
caution based on ethical considerations and the individual nursing care for drug-intake. 
 
The patients’ renal function seems to be of utmost importance for decision making since it 
proved to be predictive for the development of thromboembolic events in the general AF 
population. (36) Similarly, chronic kidney disease was found to be associated with an increased 
risk of stroke, systemic thromboembolism and also bleeding events among patients with AF. 
Therefore, the newly developed R2CHADS2 or ATRIA scores (both were tailored to predict 
thromboembolic risk in patients with non-valvular AF) include the variables “proteinuria”, 
“end-stage renal disease” or “estimated glomerular filtration rate (eGFR) of below 45ml/min”. 
(37-38) These variables are useful for weighing the individual thromboembolic risk in 
intermediate-risk patients and thus can be considered for decision making. However, since 
patients with “end-stage renal disease” (eGFR of below 15ml/min) mirror a high-risk 
population, conclusions of the present consensus statement can not be applied to this specific 
sub-group. 
Data of cardiac imaging (including echocardiography or cardiac magnetic resonance) might 
also help to identify patients at risk. Especially data on both the functional und structural status 
– for example the left atrial appendage emptying velocity (<20cm/s) or fibrosis in the left atrial 
wall – seem to add discriminatory value. (39-41) Most importantly, an increased left atrial size 
mirrors an easily assessable diagnostic marker that provides strong discriminatory power of the 
patients’ individual risk for thromboembolic events. (42-43) 
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However, even if currently no prospective data for validation of these additional risk factors in 
patients with a CHA2DS2-VASc score of 1 are available, it seems advisable to include the 
above-mentioned characteristics in decision making when considering OAC. Of note, despite 
an individualized weighing of risk, the patients’ preferences are a crucial value with regard to 
the proposed therapeutic OAC concept. This human factor needs to be considered in decision 
making especially in individuals with a CHA2DS2-VASc score of 1 in order to ensure 
compliance which strongly influences outcome. 
 
Biomarkers and Biomarker-based Risk Scores 
Nt-proBNP and Troponin: The 2016 ESC guidelines on the management of AF recommend 
that the use of biomarkers – in particular N-terminal pro-B-type natriuretic peptide (Nt-
proBNP) and cardiac Troponin (high-sensitivity) T and I – should be considered for treatment 
decisions. (5) This recommendation is based on a recent publication of Hijazi and colleagues 
that highlighted the additional prognostic value of the measurement of cardiac Troponin and 
Nt-proBNP for risk stratification in selected (especially low- and intermediate-risk) AF 
patients. (13) The composite endpoint in the study’s investigation was defined as stroke, 
systemic embolism, pulmonary embolism, myocardial infarction and vascular death (excluding 
hemorrhagic death). While there was a clear linear trend of increasing risk with increasing 
troponin values, especially in individuals with a CHA2DS2-VASc score of 0 or 1, Nt-proBNP 
values did not exhibit a clear correlation with an increased risk for thromboembolism. However, 
initial Nt-proBNP values above 1400ng/l can be considered as significant risk factor as defined 
by the ABC stroke risk score and recommended by the ESC guidelines on the management of 
AF. (5, 13) 
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ABC (Age/Biomarker/Clinical history) Score: The ABC Stroke Risk Score – which covers the 
variables age, biomarker (GDF-15, cardiac high-sensitivity Troponin and hemoglobin) and 
clinical history of stroke – may help to further refine the thromboembolic risk of patients with 
a CHA2DS2-VASc score of 1. (30) Using the aforementioned values, the ABC score allows 
discrimination of the individual risk in annual thromboembolic event rates of <0.3%, 0.3-1.0%, 
1.0-2.0% and >2%. This biomarker-based approach may guide the treating physician in 
decision making in intermediate-risk AF patients with an unclear antithrombotic benefit of 
OAC. 
 
Type and Symptoms of Atrial Fibrillation  
Paroxysmal vs. persistent/permanent AF 
A major point in decision making might be the type of AF the respective patient presents with. 
As evident in current guidelines, OAC should be considered in patients with AF irrespective of 
the individual AF-type. However, several analyses revealed that patients with permanent AF 
are at a higher risk of stroke compared to patients with non-permanent AF. This was recently 
confirmed by a meta-analysis including data of 99,996 patients. (44-45) While permanent AF 
increased the risk of embolic events by 50–100% in individuals with a CHA2DS2-VASc score 
≥2, patients presenting with paroxysmal AF still had an annual stroke rate of at least 2%. These 
data strengthen current recommendations that patients with a high clinical risk of stroke should 
be anticoagulated regardless of their AF pattern. Of note this analysis included a low number 
of patients with a CHA2DS2-VASc score of 1 (<10%).  
Interestingly, a similar investigation revealed annual stroke rates of 0.36% and 1.3% for 
paroxysmal and permanent AF, respectively, during 10 years of follow-up in young AF patients 
without additional risk factors. (46) Thus, the pattern of AF may help to quantify the 
thromboembolic risk in patients with a CHA2DS2-VASc score of 1. However, future 
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investigations in this field are needed in order to elucidate a clear prognostic potential before 
its clinical application. 
 
Atrial Fibrillation vs. Atrial Flutter 
According to current guidelines, patient with atrial flutter (AFL) and AF should both receive 
OAC in the same manner. Recent data from the Taiwan National Health Insurance Research 
Database (n=219,416) suggested a strong deviation between the actual thromboembolic risk of 
AF and AFL. The authors observed that event rates per 100 person-years of both ischemic 
stroke (AF: 3.1% vs. AFL: 1.5%) and mortality (AF: 17.8% vs. AFL: 13.9%) were significantly 
higher in AF. These results were also evident in patients with a CHA2DS2-VASc score of 1, 
showing an increased risk for ischemic events (HR: 2.88 [95%CI: 1.73-4.80]) and all-cause 
mortality (HR: 1.43 [95%CI: 1.23-1.66]) in AF patients compared to AFL individuals. Of note, 
comparing AFL to non-AF/AFL patients, the authors observed no increased risk for ischemic 
stroke (HR: 0.90 [95%CI: 0.53-1.54]) but for all-cause mortality (HR: 3.12 (95%CI: 2.63-
3.74]). Considering these results, the type of atrial arrhythmia may be considered for refinement 
of thromboembolic risk in patients with intermediate risk. (47) However, these data need to be 
confirmed in an independent cohort before drawing any therapeutic conclusions. 
 
Atrial Fibrillation Associated Symptoms 
Similarly, the impact of “silent AF” needs to be discussed, since more than one third of AF 
cases are asymptomatic. Those individuals give the impression to be at a lower risk for both 
thromboembolic and adverse cardiac events based on their individual clinical presentation. 
However, there is evidence that the risk of stroke in silent AF is similar to of the risk of 
symptomatic individuals. In this regard Glotzer et al. revealed that moderately severe AF-
related symptoms represent a poor indicator for the presence of AF, having a sensitivity of 
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82.4% but a specificity of only 38.3%. Based on these observations, AF-related symptoms 
should not be considered for decision making pro or contra OAC in AF. (47-49) 
Of note, a challenging issue in this specific subgroup mirrors the transition from paroxysmal to 
persistent AF, which is likely to be missed in silent AF patients, but potentially accompanies a 
strong impact on the individual thromboembolic risk. However, there is no clear evidence 
available in current literature on the effect of OAC in patients with silent (device detected) AF. 
However, ongoing trials (ATRESiA trial; NCT01938248) will provide profound data on the 
antithrombotic management in this low-risk AF population in the near future 
 
Refinement of the Individual Bleeding Risk 
Besides thromboembolic risk, the individual risk of bleeding needs be considered when 
assessing the net-benefit of OAC. Similar to the CHA2DS2-VASc score, the HAS-BLED score 
was established (as a 1 point per risk factor scoring tool) to identify patients at higher risk for 
bleeding events and still represents the gold standard in bleeding risk estimation using easily 
available characteristics: hypertension (>160 mmHg systolic blood pressure); renal disease; 
liver disease; history of stroke; prior major bleeding or predisposition to bleeding; labile INR 
(in VKA recipients); age >65 years; medication predisposing for bleeding; alcohol use. (8-11) 
Of note, the HAS-BLED score was additionally developed to foster a close patient follow-up 
and draw the physicians’ attention to potentially reversible risk factors for bleeding events such 
as labile INRs (in VKA), uncontrolled hypertension (>160mmHg of systolic blood pressure), 
or co-medication. A parallel intake of antiplatelet therapy, chronic concomitant use of non-
steroidal anti-inflammatory drugs or selective serotonin reuptake inhibitors (SSRIs) and other 
possible interacting drugs need to be taken into account with regard to an increased bleeding 
risk – especially gastro-intestinal bleedings. Moreover, kidney and liver function add prognostic 
value to the individual bleeding risk assessment. 
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These patient characteristics need to be considered when estimating the individual risk of 
bleeding and require – if possible – optimization and control when OAC is indicated. 
In the era of NOAC the actual bleeding risk estimation might be even more challenging, since 
the HAS-BLED score is based on patients receiving VKA. However, compared to the ABC or 
ORBIT score, the HAS-BLED score has subsequently been validated for patients receiving 
NOAC. (50-52) Since there are currently no other validated alternative prediction tools for risk 
assessment in this regard, physicians should therefore use the HAS-BLED score for estimation 
of the individual risk of bleeding. As a future perspective it might be possible to specify 
bleeding risk estimation via a biomarker-based approach. Growth differentiation factor 15 
(GDF-15) has been introduced as a marker that specifically predicts bleeding events, and 
therefore might be useful for risk stratification in intermediate-risk AF patients in the near 
future. (30) 
 
Therapeutic Strategies in CHA2DS2-VASc of 1 
If – after a comprehensive evaluation considering both the individual thromboembolic and 
bleeding risk – the treating physician decides that the patient with AF and a CHA2DS2-VASc 
score of 1 will benefit from antithrombotic treatment, there are two common therapeutic 
strategies in clinical practice: antiplatelet therapy (acetylsalicylic acid [ASA]) or OAC using 
NOACs or VKAs. To provide contemporary clinical guidance, we are able to rely on highly 
powered observational data and subgroup analysis of recent phase III randomized controlled 
NOAC landmark trials. (18, 53-64) 
ASA vs. VKA: Data on a large nationwide Danish registry indicate a net-benefit for warfarin 
with regard to the composite endpoint (=ischemic stroke, intracranial hemorrhage, major 
bleeding and myocardial infarction) compared to ASA and to no treatment in patients with a 
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CHA2DS2-VASc score of 1. Of note, there was no net clinical benefit observed for ASA 
compared to no treatment. (52) 
ASA vs. NOAC: The AVERROES trial represents the first randomized controlled trial on this 
topic, comparing ASA to apixaban for antithrombotic therapy in patients with AF. (53-54) The 
study team observed a prominent advantage for reduction of stroke and systemic embolism with 
apixaban (event rate: 1.6%), compared to ASA (event rate: 3.7%) with a relative risk reduction 
of 55%. Of note, there was no increased risk of bleeding reported with apixaban (event rate: 
1.4% [apixaban] vs. 1.2% [ASA]). However, there was no specific subgroup analysis of patients 
with a CHA2DS2-VASc score of 1.  
 NOAC vs. VKA: Based on a post-hoc analysis of the RE-LY trial, Eckmann et al investigated 
the tipping point of OAC in patients with AF within calculations of a decision model. They 
observed that warfarin was preferred in patients with a stroke rate above 1.7% per year. 
Interestingly, anticoagulation with NOAC may lead to a lowering of the threshold for OAC use 
to a stroke rate of 0.9% per year. (55) 
With regard to the large phase III NOAC trials, a subgroup analysis for CHA2DS2-VASc score 
of 1 (N=1604) was performed in the ARISTOTLE trial comparing apixaban to warfarin. (18, 
56) Considering thromboembolic events (HR: 1.18 [95% CI:0.46-2.98]; p-value for interaction 
of 0.121), major bleeding (HR: 0.65 [95% CI:0.31-1.37]; p-value for interaction of 0.206) and 
intracranial hemorrhage (HR: 0.55  [95% CI:0.13-2.29]; p-value for interaction of 0.848), 
consistent effects were observed for apixaban. 
Taking these data into account, it can be speculated that there is a consistent benefit of apixaban 
compared to warfarin in patients with intermediate-risk AF, although the study was 
underpowered for the performed subgroup analysis.  
Most recently rivaroxaban (n=3319) was found to be associated with a lower rate of both 
ischemic stroke and systemic embolism (HR 0.41 [95%CI: 0.17-0.98]) without increasing 
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major bleeding events (HR 0.74 [95% CI: 0.44-1.26]) in AF naïve individuals presenting with 
a CHA2DS2-VASc score of 1 compared to VKA (n=3319). (64)  
 
The Exceptional Position of Coronary Artery Disease: The decision for or against OAC in 
patients with a CHA2DS2-VASc score of 1 with coronary artery disease (CAD) and the 
indication for single or dual anti-platelet therapy (DAPT) remains challenging. Combining two 
antiplatelet agents with OAC significantly increases the risk of (major) bleeding most likely 
outweighing the thromboembolic risk in AF patients without a further risk factor in the 
CHA2DS2-Vasc score. (59-61) In this regard DAPT for 12 months (including clopidogrel and 
new P2Y12 inhibitors) may be considered as a sufficient antithrombotic regimen for 
intermediate-risk AF patients with acute coronary syndrome and/or percutaneous coronary 
intervention (or stent implantation) and AF. However, based on recent studies the combination 
of an OAC with low bleeding risk and only one anti-platelet therapy may provide an optimized 
net benefit. However, there are no subgroup analysis available for patients with CHA2DS2-
VASc score of 1 within these trials. (59-61) Decisions should be made considering the patients’ 
individual atherothrombotic risk after stent implantation via recommended risk scores (REACH 
or SYNTAX Score if elective; GRACE ≥140 if ACS) or patient characteristics (stenting of left 
main, proximal LAD, proximal bifurcation, recurrent myocardial infarction or stent 
thrombosis). Moreover, a single episode of AF triggered by AMI may not justify long-term 
OAC in intermediate-risk patients as the reoccurrence rate of AF remains to be determined. 
However, the re-occurrence of AF should be screened regularly. One year after stent 
implantation and/or ACS antithrombotic therapy should restricted to monotherapy either with 
an antiplatelet agent or with OAC based on risk refinement for patients with a CHA2DS2-Vasc 
score of 1. If no OAC has been started, the accumulation of additional risk factors for 
thromboembolic events over time (e.g. age >65 years) needs to be assessed regularly and long-
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term therapy should be switched from antiplatelet therapy to OAC if the CHA2DS2-Vasc score 
increases further. 
 
Summary of Evidence on Therapeutic Strategies 
Since consistent beneficial effects were observed for NOACs compared to VKAs in terms of 
thromboembolic and bleeding events in patients with intermediate risk AF, a superior net 
benefit of NOACs over VKAs can be assumed. Data from the large phase III trials – RE-LY, 
ARISTOTLE, ENGAGE AF and ROCKET-AF – indicate that major bleeding was significantly 
reduced with dabigatran (110 mg bid), apixaban and edoxaban, while rates of major bleeding 
were similar with high-dose dabigatran (150mg bid) and rivaroxaban compared to VKAs. (15-
18) Additionally, NOACs showed a strong reduction in annual ICH rates compared to warfarin 
with an overall hazard ratio of 0.48 in the four trials. (63) Considering these data, NOACs seem 
to offer a therapeutic benefit with regard to stroke prevention and bleeding risk compared to 
VKA in this intermediate-risk patient population. (62-64) There are currently no data whether 
a reduced dosage of NOACs offers a net benefit in these patients when compared to full-dose 
NOAC and VKA therapies. Observational studies and recent randomized controlled trials 
highlighted that ASA is not a beneficial treatment option in intermediate-risk individuals. 
Therefore, ASA should not be considered for stroke prevention in AF patients with a CHA2DS2-
VASc score of 1 free of CAD. However, intermittent DAPT for one year after stent implantation 
and/or ACS seems justified in patients with a CHA2DS2-VASc score of 1 and a high 
atherothrombotic risk.  
 
Conclusion 
Since the risk of stroke is heterogeneous in individuals with AF and a CHA2DS2-VASc score 
of 1, risk assessment should be carefully performed in the respective patients and further refined 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz016/5497479 by Aalborg U
niversity Library user on 24 M
ay 2019
 
   
 
19
by available predictive tools or biomarker-based approaches. This refinement also comprises 
additional (cardiovascular) risk factors at the time of presentation and the patients’ individual 
preferences. A personalized decision-making and comprehensive weighing of the respective 
risk factors seems crucial. 
Anti-thrombotic treatment with NOACs seems to offer a superior net benefit with regard to 
prevention of thromboembolic events and the risk of major bleeding compared to VKAs. It 
currently provides the most beneficial and reasonable treatment approach in individuals with 
AF and a CHA2DS2-VASc score of 1. Considering data on major bleeding in the phase III trials, 
NOAC therapy with a low risk of intracranial bleeding should therefore be preferred over VKAs 
in these patients. Based on current evidence, ASA does not offer any advantage for patients 
with CHA2DS2-VASc score of 1 free of CAD compared to OAC. DAPT for 12 months, 
including clopidogrel and new P2Y12 inhibitors, may be considered in AF patients with an 
intermediate thromboembolic but high atherothrombotic risk and an ACS and/or coronary 
intervention within the last year. 
Figure 1 and Table 2 illustrate an evidence-based approach of both risk assessment and 
antithrombotic therapy in patients with a CHA2DS2-VASc Score of 1. 
 
Consensus Statement 
• There is currently no evidence from randomized controlled trials to guide 
anticoagulation in patients with AF and a CHA2DS2-VASc score of 1. However, 
experience from recent observational trials indicates that the thromboembolic risk of 
AF patients with a CHA2DS2-VASc score of 1 might be lower than anticipated. A 
general recommendation of OAC therapy in these individuals might weaken the net 
clinical benefit due to an increased risk of bleeding events. Therefore, refinement of the 
individual thromboembolic risk assessment is needed. 
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• The HAS-BLED score was established as a clinical risk prediction tool for the 
occurrence of bleeding events and has been developed in patients receiving VKA 
therapy. Therefore, the bleeding risk associated with NOAC therapy may be even more 
difficult to assess.  However, its predictive value has recently been validated in several 
investigations including a representative proportion of individuals receiving NOACs. 
Considering annual bleeding rates of 1.88% to 3.20% per year in patients presenting 
with a HAS-BLED score of 2, the annual risk of bleeding outweighs the 
thromboembolic risk associated with a CHA2DS2-VASc score of 1, which amounts to 
only 0.6% to 1.3% per year. (Table 1) Therefore, OAC should not be considered in 
intermediate thromboembolic risk patients with a HAS-BLED score ≥2. 
• Considering the predictive value of individual markers in both male and female patients, 
age and diabetes mellitus type II may be the most important isolated risk factors for 
thromboembolic events. LA size seems a reasonable and easily assessable imaging 
marker for risk stratification. Routinely available biomarkers such as cardiac troponin 
(high sensitivity troponin T or I) and Nt-proBNP as well the burden of AF (paroxysmal 
AF vs. non-paroxysmal AF) may provide additional prognostic information to enhance 
risk estimation and decision making for OAC particularly in intermediate-risk 
individuals. Importantly, the patients’ individual preference for, or against initiation of 
OAC must be taken into account. 
• Therapeutic decisions should be based on the individual balance between 
thromboembolic and bleeding risk – the therapeutic preference should be on doing no 
harm rather than avoiding stroke. If the decision of OAC initiation in AF patients 
presenting with a CHA2DS2-VASc Score of 1 has been made, NOACs with a superior 
net-clinical benefit should be preferred over VKAs.  
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz016/5497479 by Aalborg U
niversity Library user on 24 M
ay 2019
 
   
 
21
• There is no evidence that patients with AF presenting with a CHA2DS2-VASc score of 
1 (except with CAD) benefit from ASA therapy. Therefore, ASA for stroke prevention 
should not be considered in this intermediate-risk patient population.  
• DAPT for 12 months, including clopidogrel and new P2Y12 inhibitors, may be 
considered in AF patients with an intermediate thromboembolic risk and an ACS and/or 
coronary intervention. 
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Table Legends 
 
Table 1: Event rates within categories of CHA2DS2-VASc and HAS-BLED score. Adjusted 
event rates within categories of CHA2DS2-VASc Score and HAS-BLED Score. Data obtained 
via Pisters R (CHEST, 2010), Lip GYH (CHEST, 2010), Lip GYH (Stroke, 2010) – Euro Heart 
Survey (8-10) 
 
Table 2: Values for individual risk stratification. Values that favor oral anticoagulation and 
allow individual thromboembolic risk stratification in AF patients with a CHA2DS2-Vasc of 1. 
eGFR = estimated Glomerular Filtration Rate; LA = Left Atrium; LAA = Left Atrial 
Appendage; Nt-proBNP = N-terminal pro-B-type natriuretic peptide. 
 
 
Figure Legends 
 
Figure 1: Decision tree for OAC in patients with AF and a CHA2DS2-VASc score of 1. 
NOAC = non-Vitamin K antagonist oral anticoagulants; OAC = Oral Anticoagulation; VKA = 
Vitamin K Antagonist. 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz016/5497479 by Aalborg U
niversity Library user on 24 M
ay 2019
Table 1: Event rates within categories of CHA2DS2-VASc and HAS-BLED score. 
 
CHA2DS2-VASc score      HAS-BLED score 
 
Category Thromboembolic event rate/year  Category Bleeding event rate/year 
 
0  0      0  0.59 – 1.13 
1  0.6 – 1.3     1  1.02 – 1.51 
2  1.6 – 2.2     2  1.88 – 3.20 
3  3.2 – 3.9     3  3.74 – 19.51 
4  1.9 – 4.0     4  8.70 – 21.43 
5  3.2 – 6.7       
6  3.6 – 9.8      
7  8.0 – 9.6 
8  6.7 – 11.1 
9  >15.2 
Table 1: Adjusted event rates within categories of CHA2DS2-VASc Score and HAS-BLED Score. Data obtained via Pisters R (CHEST, 2010), 
Lip GYH (CHEST, 2010), Lip GYH (Stroke, 2010) – Euro Heart Survey (8-10) 
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Table 2: Values for individual risk stratification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Values for individual risk stratification: Values that favor oral anticoagulation and allow individual thromboembolic risk stratification in 
patients with a CHA2DS2-Vasc of 1. eGFR = estimated Glomerular Filtration Rate; LA = Left Atrium; LAA = Left Atrial Appendage; Nt-proBNP = 
N-terminal pro-B-type natriuretic peptide 
 
Favors oral anticoagulation 
(in case of low bleeding risk) 
     Age (>65 years) 
     Type II diabetes mellitus 
     Atrial fibrillation (not atrial flutter) 
     Persistent/permanent atrial fibrillation 
  
Additional factors for thromboembolic risk modification 
  
     Obesity (body mass index ≥30) 
     Proteinuria (>150mg/24h or equivalent) 
     eGFR (<45ml/h) 
     NT-proBNP (>1400ng/l) 
     Positive cardiac troponin T and I 
     Enlarged LA volume (≥73mL) or diameter (≥4.7cm) 
     LAA emptying velocity (<20cm/s) 
     ABC (Age/Biomarker/Clinical history) score 
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